Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) Call to Discuss NTLA-2002 Phase 2 Study Results Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Conference Call Participants Luca Issi - RBC Maury Raycroft - Jefferies Mani Foroohar - Leerink Partners Chris Yu - Morgan Stanley Gena Wang - Barclays Dae Gon Ha - Stifel Kostas Biliouris - BMO Capital Markets Rick Bienkowski - Cantor Fitzgerald William Pickering - Bernstein Ray Forset - Guggenheim Timur Ivannikovon - Raymond James Jay Olson - Oppenheimer Operator Good morning, and welcome to the Intellia Therapeutics Investor Event.
2 Biotech Stocks Making Big Moves
The ever-volatile biotech sector is making noise today.
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
On Thursday, Intellia Therapeutics, Inc. NTLA released Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
These stocks haven't performed well this year.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Cathie Wood invests in businesses that are risky, but with a lot of upside. Intellia Therapeutics has a couple of key readouts coming up.
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Intellia Therapeutics is pioneering in-vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster status. Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships, like with Regeneron, make it a compelling buy opportunity. The company's innovative use of lipid nanoparticles for gene delivery and a robust pipeline position it as a leader in the CRISPR space, targeting large markets.
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations & Corporate Communications John Leonard - President & Chief Executive Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Mary Kate Davis - Bank of America Dae Gon Ha - Stifel Joseph Thome - TD Cowen Luca Issi - RBC Gena Wang - Barclays Maury Raycroft - Jefferies Mani Foroohar - Leerink Rick Bienkowski - Cantor Fitzgerald Jay Olson - Oppenheimer Timor Vanicus - Raymond James Silvan Tuerkcan - Citizens JMP William Pickering - Bernstein Myles Minter - William Blair David Lebowitz - Citi Operator Good morning, and welcome to Intellia Therapeutics' Second Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago.
